Therapeutic concepts in adult and paediatric eosinophilic oesophagitis

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 12, 2012, Pages 697-704

  Straumann, Alex ^a   Schoepfer, Alain M ^b  

^a Swiss EoE Research Network   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FLUTICASONE; IMMUNOMODULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; MONTELUKAST; OC 000459; PLACEBO; PREDNISONE; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROTON PUMP INHIBITOR; RESLIZUMAB; UNCLASSIFIED DRUG;

CLINICAL FEATURE; DIET THERAPY; DRUG EFFICACY; EOSINOPHILIC ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS DILATATION; ESOPHAGUS STENOSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THORAX PAIN; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGE FACTORS; ANTI-ALLERGIC AGENTS; CHILD; CHILD, PRESCHOOL; DIET THERAPY; DISEASE MANAGEMENT; EOSINOPHILIC ESOPHAGITIS; FEMALE; HUMANS; MALE; PREVALENCE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870598778     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.182     Document Type: Review

References (85)

1. Liacouras, C. A. et al. Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J. Allergy Clin. Immunol. 128, 3-20 (2011).
2. Kelley, M. L. Jr & Frazer, J. P. Symptomatic mid-Esophageal webs. JAMA 197, 143-146 (1966).
3. Landres, R. T., Kuster, G. G. & Strum, W. B. Eosinophilic esophagitis in a patient with vigorous achalasia. Gastroenterology 74, 1298-1301 (1978). (Pubitemid 8352861)
4. Bousvaros, A., Antonioli, D. A. & Winter, H. S. Ringed esophagus: An association with esophagitis. Am. J. Gastroenterol. 87, 1187-1190 (1992).
5. Langdon, D. E. Corrugated ringed esophagus. Am. J. Gastroenterol. 88, 1461 (1993).
6. Attwood, S. E., Smyrk, T. C., Demeester, T. R. & Jones, J. B. Esophageal eosinophilia with dysphagia, a distinct clinicopathologic syndrome. Dig. Dis. Sci. 38, 109-116 (1993). (Pubitemid 23039460)
7. Straumann, A., Spichtin, H. P., Bernoulli, R., Loosli, J. & Vögtlin, J. Idiopathic eosinophilic esophagitis: A frequently overlooked disease with typical clinical aspects and discrete endoscopic findings [article in German with English abstract]. Schweiz. Med. Wochenschr. 124, 1419-1429 (1994). (Pubitemid 24267319)
8. Rothenberg, M. E., Mishra, A., Collins, M. H. & Putnam, P. E. Pathogenesis and clinical features of eosinophilic esophagitis. J. Allergy Clin. Immunol. 108, 891-894 (2001). (Pubitemid 33151538)
9. Prasad, G. A. et al. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin. Gastroenterol. Hepatol. 7, 1055-1061 (2009).
10. Hruz, P. et al. Escalating incidence of eosinophilic esophagitis: A 20-year prospective, population-based study in Olten County, Switzerland. J. Allergy Clin. Immunol. 128, 1349-1350 (2011).
11. DeBrosse, C. W. et al. Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982-1999. J. Allergy Clin. Immunol. 126, 112-119 (2010).
12. Straumann, A. et al. Fragility of the esophageal musoca: A pathognomonic endoscopic sign of primary eosinophilic esophagitis? Gastrointest. Endosc. 57, 407-412 (2003). (Pubitemid 36350808)
13. Straumann, A. et al. Eosinophilic esophagitis: Analysis of food impaction and perforation in 251 adolescent and adult patients. Clin. Gastroenterol. Hepatol. 6, 598-600 (2008).
14. Noel, R. J., Putnam, P. E. & Rothenberg, M. E. Eosinophilic esophagitis. N. Engl. J. Med. 351, 940-941 (2004).
15. Croese, J. et al. Clinical and endoscopic features of eosinophilic esophagitis in adults. Gastrointest. Endosc. 58, 516-522 (2003). (Pubitemid 37205763)
16. Franciosi, J. P., Tam, V., Liacouras, C. A. & Spergel, J. M. A case-control study of sociodemographic and geographic characteristics of 335 children with eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 7, 415-419 (2009).
17. Collins, M. H. et al. Clinical, pathologic and molecular characterization of familial eosinophilic esophagitis compared with sporadic cases. Clin. Gastroenterol. Hepatol. 6, 621-629 (2008).
18. Blanchard, C. et al. Eotaxin 3 and a uniquely conserved gene-Expression profile in eosinophilic esophagitis. J. Clin. Invest. 116, 536-547 (2006). (Pubitemid 43228372)
19. Palmer, C. N. et al. Common loss of function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38, 441-446 (2006).
20. Blanchard, C. et al. Coordinate interaction between IL 13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J. Immunol. 184, 4033-4041 (2010).
21. Rothenberg, M. E. et al. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat. Genet. 42, 289-291 (2010).
22. Gudbjartsson, D. F. et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat. Genet. 41, 342-347 (2009).
23. Yan, B. M. & Shaffer, E. A. Primary eosinophilic disorders of the gastrointestinal tract. Gut 58, 721-732 (2009).
24. Yamaguchi, Y. et al. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J. Exp. Med. 167, 43-56 (1988). (Pubitemid 18093692)
25. Rothenberg, M. E., Mishra, A., Brandt, E. B. & Hogan, S. P. Gastrointestinal eosinophils in health and disease. Adv. Immunol. 78, 291-328 (2001). (Pubitemid 32567511)
26. Mishra, A., Hogan, S. P., Lee, J. J., Foster, P. S. & Rothenberg, M. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J. Clin. Invest. 103, 1719-1727 (1999). (Pubitemid 29534366)
27. Garcia-Zepeda, E. A. et al. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat. Med. 2, 449-456 (1996). (Pubitemid 26193013)
28. Forssmann, U. et al. Eotaxin 2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J. Exp. Med. 185, 2171-2176 (1997). (Pubitemid 27266000)
29. Shinkai, A. et al. A novel human CC chemokine, eotaxin 3, which is expressed in IL 4 stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J. Immunol. 163, 1602-1610 (1999). (Pubitemid 29352785)
30. Bochner, B. S. & Schleimer, R. P. The role of adhesion molecules in human eosinophil and basophil recruitment. J. Allergy Clin. Immunol. 94, 427-438 (1994). (Pubitemid 124006650)
31. Powell, N., Walker, M. M. & Talley, N. J. Gastrointestinal eosinophils in health, disease and functional disorders. Nat. Rev. Gastroenterol. Hepatol. 7, 146-156 (2010).
32. Mishra, A. et al. Esophageal remodeling develops as a consequence of tissue specific IL 5 induced eosinophilia. Gastroenterology 134, 204-214 (2008). (Pubitemid 350309313)
33. Aceves, S. S., Newbury, R. O., Dohil, R., Bastian, J. F. & Broide, D. H. Esophageal remodeling in paediatric eosinophilic oesophagitis. J. Allergy Clin. Immunol. 119, 206-212 (2007). (Pubitemid 46037819)
34. Kagalwalla, A. F. et al. Eosinophilic esophagitis: Epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment. J. Allergy Clin. Immunol. 129, 1387-1396 (2012).
35. Aceves, S. S. et al. Resolution of remodeling in eosinophilic oesophagitis correlates with epithelial response to topical corticosteroids. Allergy 65, 109-116 (2010).
36. Straumann, A. et al. Budesonide is effective in adolescent and adult patients with active eosinophilic oesophagitis. Gastroenterology 139, 1526-1537 (2010).
37. Straumann, A. et al. Natural history of primary eosinophilic esophagitis: A follow-up of thirty patients for up to 11.5 years. Gastroenterology 125, 1660-1669 (2003). (Pubitemid 37500430)
38. DeBrosse, C. W. et al. Long-Term outcomes in pediatric-Onset esophageal eosinophilia. J. Allergy Clin. Immunol. 128, 132-138 (2011).
39. Aceves, S. S. et al. Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy 65, 109-116 (2010).
40. Lucendo, A. J. et al. Subepithelial collagen deposition, profibrogenic cytokine gene expression, and changes after prolonged fluticasone propionate treatment in adult eosinophilic esophagitis: A prospective study. J. Allergy Clin. Immunol. 128, 1037-1046 (2011).
41. Abu-Sultaneh, S. M., Durst, P., Maynard, V. & Elitsur, Y. Fluticasone and food allergen elimination reverse sub-Epithelial fibrosis in children with eosinophilic esophagitis. Dig. Dis. Sci. 56, 97-102 (2011).
42. Furuta, G. T. et al. Eosinophilic esophagitis in children and adults: A systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 133, 1342-1363 (2007
43. Kelly, K. J. et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: Improvement with an amino acid-based formula. Gastroenterology 109, 1503-1512 (1995).
44. Arora, A. S. & Yamazaki, K. Eosinophilic esophagitis: Asthma of the esophagus? Clin. Gastroenterol. Hepatol. 2, 523-530 (2004). (Pubitemid 38834035)
45. Straumann, A., Bauer, M., Fischer, B., Blaser, K. & Simon, H. U. Idiopathic eosinophilic esophagitis is associated with a TH 2 type allergic inflammatory response. J. Allergy Clin. Immunol. 108, 954-961 (2001). (Pubitemid 33151548)
46. Krarup, A. L. et al. Acid hypersensitivity in patients with eosinophilic oesophagitis. Scand. J. Gastroenterol. 45, 273-281 (2010).
47. Molina-Infante, J. et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin. Gastroenterol. Hepatol. 9, 110-117 (2011).
48. Sayej, W. N., Patel, R., Baker, R. D., Tron, E. & Baker, S. S. Treatment with high-Dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J. Pediatr. Gastroenterol. Nutr. 49, 393-399 (2009).
49. Liacouras, C. A., Wenner, W. J., Brown, K. & Ruchelli, E. Primary eosinophilic esophagitis in children: Successful treatment with oral corticosteroids. J. Pediatr. Gastroenterol. Nutr. 26, 380-385 (1998). (Pubitemid 28160684)
50. Faubion, W. A. et al. Treatment of eosinophilic esophagitis with inhaled corticosteroids. J. Pediatr. Gastroenterol. Nutr. 27, 90-93 (1998).
51. Schaefer, E. T. et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: A randomized trial in children. Clin. Gastroenterol. Hepatol. 6, 165-173 (2008). (Pubitemid 351172942)
52. Konikoff, M. R. et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 131, 1381-1391 (2006). (Pubitemid 44780861)
53. Remedios, M., Campbell, C., Jones, D. M. & Kerlin, P. Eosinophilic esophagitis in adults: Clinical, endoscopic, histologic findings and response to treatment with fluticasone proprionate. Gastrointest. Endosc. 63, 3-12 (2006). (Pubitemid 41827769)
54. Lucendo, A. J. et al. Endoscopic, bioptic, and manometric findings in eosinophilic esophagitis before and after steroid therapy: A case series. Endoscopy 39, 765-771 (2007). (Pubitemid 47386823)
55. Dohil, R., Newbury, R., Fox, L., Bastian, J. & Aceves, S. S. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 139, 418-429 (2010).
56. Straumann, A. et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 139, 1526-1537 (2010).
57. Peterson, K. A. et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic oesophagitis. Dig. Dis. Sci. 55, 1313-1319 (2010).
58. Schroeder, S. et al. Successful treatment of eosinophilic esophagitis with ciclesonide. J. Allergy Clin. Immunol. 129, 1419-1421 (2012).
59. Dellon, E. S. et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology 143, 321-324e1 (2012).
60. Straumann, A. et al. Long-Term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 9, 400-409 (2011).
61. Attwood, S. E. et al. Eosinophilic oesophagitis: A novel treatment using Montelukast. Gut 52, 181-185 (2003). (Pubitemid 36115056)
62. Lucendo, A. J. et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig. Dis. Sci. 56, 3551-3558 (2011).
63. Gupta, S. K., Fitzgerald, J. F., Kondratyuk, T. & HogenEsch, H. Cytokine expression in normal and inflamed esophageal mucosa: A study into the pathogenesis of allergic eosinophilic esophagitis. J. Pediatr. Gastroenterol. Nutr. 42, 22-26 (2006). (Pubitemid 43061005)
64. Pettipher, R., Hansel, T. T. & Armer, R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug Discov. 6, 313-325 (2007). (Pubitemid 46505882)
65. Straumann, A. et al. Treatment of eosinophilic esophagitis with the CRTH2-Antagonist OC000459: A novel therapeutic principle [abstract A856]. Gastroenterology 142 (SUPPL1), S-439 (2012).
66. Straumann, A. et al. Anti interleukin 5 antibody treatment (mepolizumab) in active eosinophilic esophagitis: A randomized, placebo-controlled, double-blind trial. Gut 59, 21-30 (2010).
67. Assa'ad, A. H. et al. An antibody against IL 5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 141, 1593-1604 (2011).
68. Spergel, J. M. et al. Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 129, 456-463 (2012).
69. Straumann, A., Bussmann, C., Conus, S., Beglinger, C. & Simon, H. U. Anti TNF α (infliximab) therapy for severe adult eosinophilic esophagitis. J. Allergy Clin. Immunol. 122, 425-427 (2008).
70. Netzer, P. et al. Corticosteroid-Dependent eosinophilic oesophagitis: Azathioprine and 6 mercaptopurine can induce and maintain long-Term remission. Eur. J. Gastroenterol. Hepatol. 19, 865-869 (2007). (Pubitemid 47415145)
71. Spergel, J. M. et al. 14 years of eosinophilic espophagitis: Clinical features and prognosis. J. Pediatr. Gastroenterol. Nutr. 48, 30-36 (2009).
72. Markowitz, J. E., Spergel, J. M., Ruchelli, E. & Liacouras, C. A. Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am. J. Gastroenterol. 98, 777-782 (2003). (Pubitemid 36576301)
73. Liacouras, C. A. et al. Eosinophilic esophagitis: A 10-year experience in 381 children. Clin. Gastroenterol. Hepatol. 3, 1198-1206 (2005). (Pubitemid 41797671)
74. Spergel, J. M., Andrews, T., Brown-Whitehorn, T. F., Beausoleil, J. L. & Liacouras, C. A. Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Ann. Allergy Asthma Immunol. 95, 336-343 (2005). (Pubitemid 41483727)
75. Spergel, J. M., Beausoleil, J. L., Mascarenhas, M. & Liacouras, C. A. The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J. Allergy Clin. Immunol. 109, 363-368 (2002). (Pubitemid 34158307)
76. Kagalwalla, A. F. et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 4, 1097-1102 (2006). (Pubitemid 44311644)
77. Kagalwalla, A. F. et al. Identification of specific foods responsible for inflammation in children with eosinophilic esophagitis successfully treated with empiric elimination diet. J. Pediatr. Gastroenterol. Nutr. 53, 145-149 (2011).
78. Gonsalves, N. et al. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 142, 1451-1459 (2012).
79. Henderson, C. J. et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J. Allergy Clin. Immunol. 129, 1570-1578 (2012).
80. Schoepfer, A. M., Gschossmann, J., Scheurer, U., Seibold, F. & Straumann, A. Esophageal strictures in adult eosinophilic oesophagitis: Dilation is an effective and safe alternative after failure of topical corticosteroids. Endoscopy 40, 161-164 (2008). (Pubitemid 351292221)
81. Schoepfer, A. M. et al. Esophageal dilation in eosinophilic oesophagitis: Effectiveness, safety, and impact on the underlying inflammation. Am. J. Gastroenterol. 105, 1062-1070 (2010).
82. Dellon, E. S. et al. Esophageal dilation in eosinophilic oesophagitis: Safety and predictors of clinical response and complications. Gastrointest. Endosc. 71, 706-712 (2010).
83. Robles-Medranda, C. et al. Severe dysphagia in children with eosinophilic esophagitis and esophageal stricture : An indication for balloon dilation? J. Pediatr. Gastroenterol. Nutr. 50, 516-520 (2010).
84. Jacobs, J. W. Jr & Spechler, S. J. A systematic review of the risk of perforation during esophageal dilation for patients with eosinophilic esophagitis. Dig. Dis. Sci. 55, 1512-1525 (2010).
85. University of Oxford Centre for Evidence based Medicine. Levels of evidence [online], http://www.cebm.net/index.aspx?o=1025 (2009).